Everything below concerns reference standard. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-01. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Iron-deficiency anemia may be present without a person experiencing symptoms. It tends to develop slowly; therefore, the body has time to adapt, and the disease often goes unrecognized for some time. If symptoms present, patients may present with the sign of pallor (reduced oxyhemoglobin in skin or mucous membranes), and the symptoms of feeling tired, weak, dizziness, lightheadedness, poor physical exertion, headaches, decreased ability to concentrate, cold hands and feet, cold sensitivity, increased thirst and confusion. None of these symptoms (or any of the others below) are sensitive or specific. In severe cases, shortness of breath can occur. Pica may also develop; of which consumption of ice, known as pagophagia, has been suggested to be the most specific for iron deficiency anemia. Other possible symptoms and signs of iron-deficiency anemia include:
=== EC 1.6.6 With a nitrogenous group as acceptor === EC 1.6.6.1: Now EC 1.7.1.1, nitrate reductase (NADH) EC 1.6.6.2: Now EC 1.7.1.2, nitrate reductase [NAD(P)H] EC 1.6.6.3: Now EC 1.7.1.3, nitrate reductase (NADPH) EC 1.6.6.4: Now EC 1.7.1.4, nitrite reductase [NAD(P)H] EC 1.6.6.5: Now EC 1.7.2.1, nitrite reductase (NO-forming) EC 1.6.6.6: Now EC 1.7.1.5, hyponitrite reductase EC 1.6.6.7: Now EC 1.7.1.6, azobenzene reductase EC 1.6.6.8: Now EC 1.7.1.7, GMP reductase EC 1.6.6.9: Now known to be catalysed by EC 1.7.2.3, trimethylamine-N-oxide reductase EC 1.6.6.10: Now EC 1.7.1.9, nitroquinoline-N-oxide reductase] EC 1.6.6.11: Now EC 1.7.1.10, hydroxylamine reductase (NADH) EC 1.6.6.12: Now EC 1.7.1.11, 4-(dimethylamino)phenylazoxybenzene reductase EC 1.6.6.13: Now EC 1.7.1.12, N-hydroxy-2-acetamidofluorene reductase
=== Singapore === Radiologists in Singapore complete a five-year undergraduate MD program, followed by a one-year internship, and then a five-year residency program. Some radiologists may elect to complete a one or two-year fellowship for further sub-specialization in fields such as interventional radiology. Slovenia After finishing a six-year study of medicine and passing the emergency medicine internship, MDs can apply for radiology residency. Radiology is a five-year post-graduate program that involves all fields of radiology with a final board exam. France To become a radiologist, after having validated the common core of medical studies, one must obtain a DES (Specialized Studies Diploma) in radiology and medical imaging (specialized studies in 5 years), or a DES in advanced interventional radiology (specialized studies in 6 years). At the end of their DES, once validated, the future doctor will have to defend their "practice thesis" to validate their DE (State Diploma) as a doctor of medicine (common to all doctors of medicine, therefore) and to be able to practice in France.
Til the Casket Drops (2009) was the final Clipse album before the duo split to make solo material. The breakup was initiated by Malice, who had multiple conversations with Pusha T about quitting the duo; the first time was after a studio session with Rick Rubin. Toward the end of the duo's partnership, their then-manager and various people in their personal lives were arrested on drug charges. One day, when both brothers were to board a plane, Pusha T was unusually late, and Malice worried that he had been arrested; although Pusha T eventually boarded, it was the final straw for Malice, who angrily declared to his brother in front of the other passengers that he was done with the duo. Although the breakup wasn't made public at the time, rumors that the duo was over began when Malice (then named Malicious) changed his stage name to No Malice, converted to Christianity, and started making Christian rap, as opposed to the "coke rap" of Clipse. In 2014, he firmly denied the possibility of a reunion. His attitude had softened by 2016: "I'ma tell you that I learned to never say never, and I don't shut the door on anything. I really don't. In fact, I would like to see Clipse do it. But I just do things differently." The duo appeared together (credited as Clipse) on "Use This Gospel" by Kanye West, from his Christian hip-hop and gospel album Jesus Is King (2019), having also worked on a demo version of "Follow God". Speaking on the reunion, Pusha T said: "I'm the younger brother, man.
Sources: en.wikipedia.org
Sedimentation equilibrium experiments reports the molar mass of analytes and their chemical equilibrium constants. The rotor speed is adjusted such that a steady-state concentration profile c(r) of the sample in the cell is formed, where sedimentation and diffusion cancel out each other. Ultracentrifuge Gas centrifuge Theodor Svedberg Differential centrifugation Buoyant density ultracentrifugation Zippe-type centrifuge Reversible Associations in Structural and Molecular Biology (RASMB -an Analytical Ultracentrifugation Forum) Analytical Ultracentrifugation as a Contemporary Biomolecular Research Tool. Archived 2002-08-04 at the Wayback Machine Gilbert-Jenkins theory Archived 2007-05-01 at the Wayback Machine Report on an ultracentrifuge explosion.
Interest in VR grew in the 1990s, particularly after the 1992 film Lawnmower Man, which helped popularize the idea of VR headsets with the general public. Sega developed a low-cost VR device, the Sega VR, in the early 1990s, for its arcade games and home consoles; the unit did not advance beyond the prototype stage, though Sega incorporated some of its head-tracking technology into its arcade cabinets. Most notable was the VR-1 virtual reality 3D arcade attraction released by Sega in 1994. Reflection Technology, Inc. (RTI) had been developing a head-mounted, stereoscopic head-tracking system using light-emitting diode (LED) displays, the Private Eye. One application they had tested included a tank game. Seeking funding for larger production, RTI licensed the technology to Nintendo, and under Gunpei Yokoi, Nintendo developed the Virtual Boy, released in 1995. The Virtual Boy used red LED displays rather than full-color ones, as they were the most inexpensive to produce, and required mounting to a stand to be played, rather than head-mounted. The system was thus awkward to use both from looking into the viewer and the eyestrain from the red LEDs. Only 22 games were produced for the Virtual Boy, and it was considered to be one of Nintendo's commercial failures. VR systems without head-mounted hardware were also developed in the 1990s, including the Cave automatic virtual environment (CAVE).
=== Alienizers === Space Criminal Alienizers (宇宙犯罪者アリエナイザー, Uchū Hanzaisha Arienaizā) is an umbrella term that S.P.D. gives to aliens that commit various crimes on Earth and other planets. Unlike most monsters in the Super Sentai franchise, many of the Alienizers pilot giant robots called Kaijuki (怪重機, Kaijūki; "Monstrous Heavy Industrial Machines"), which are usually provided by Agent Abrella.
Sources: en.wikipedia.org
==== Structural impacts on hydrogen storage capacity ==== To date, hydrogen storage in MOFs at room temperature is a battle between maximizing storage capacity and maintaining reasonable desorption rates, while conserving the integrity of the adsorbent framework (e.g., completely evacuating pores, preserving the MOF structure, etc.) over many cycles. There are two major strategies governing the design of MOFs for hydrogen storage:
Low complexity regions (LCRs) in protein sequences, also defined in some contexts as compositionally biased regions (CBRs), are regions in protein sequences that differ from the composition and complexity of most proteins that is normally associated with globular structure. LCRs have different properties from normal regions regarding structure, function and evolution.
For example, the pressure needed to drive a viscous fluid up against gravity would contain both that as needed in Poiseuille's law plus that as needed in Bernoulli's equation, such that any point in the flow would have a pressure greater than zero (otherwise no flow would happen). Another example is when blood flows into a narrower constriction, its speed will be greater than in a larger diameter (due to continuity of volumetric flow rate), and its pressure will be lower than in a larger diameter (due to Bernoulli's equation). However, the viscosity of blood will cause additional pressure drop along the direction of flow, which is proportional to length traveled (as per Poiseuille's law). Both effects contribute to the actual pressure drop.
The emperor was dressed in his interment attire: the court dress uniform of a Marshal of the Imperial Brazilian Army, with the star of the Imperial Order of the Cross on his chest. He also wore the Order of the Golden Fleece and the collar of the Imperial Order of the Rose, while his hands clutched a silver crucifix sent by Pope Leo XIII. Despite recognizing the body's overall preservation, however, d'Escragnolle Dória felt that the embalming had not fully succeeded in maintaining the emperor's appearance. He wrote: His face resembles old wax. His beard, once so fine, silky, and white, has turned a dull yellow, like aged ivory. When I saw him in February 1912, I found him smaller than he had been in late 1909. The head of Dom Pedro II rests on a pillow filled with Brazilian soil. The emperor looks so different! How cruel is an imperfect embalming! Where is that majestic head, once crowned with silvery hair? Where are his steel-blue eyes, his beautiful beard—gilded by youth and silvered by age—and his stately bearing? Everything is gone, faded!
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.